Kaneka Corporation

Other

University of Washington

Zymogenetics, Inc.

Icos Corporation

Genetic Systems Corporation

Lynn Massman Rose

David J Porubek

Alan B Montgomery

Jeffrey A Ledbetter

Paul D Bishop

Edward A Clark

Jan Öhrström

A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by, infections caused bycomplex, infections caused byand infections caused byby administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Method for treatment of bacterial infections with once or twice-weekly administered rifalazil

Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX.

Method for treating Hemophilia B

Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory disease processes associated with the multiple sclerosis disease, by adminstering to a patient a phamaceutically effective amount of mAb 23F2G or an antibody that competes with mAb 23F2G for binding to LFA-1.

Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by , infections caused by complex, infections caused by and infections caused by by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by,, infections caused by,complex, infections caused by,and infections caused by,by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease, by administering a pharmaceutically effective amount of antibody substance immunologically reactive with the common .beta. chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1.

Murine and humanizer 23F2G antibodies and cell lines expressing said

Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associated with a change in status.

Growing community of inventors

Seattle, WA, United States of America

Lynn Massman Rose